Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 19, 2018
- Accepted in final form September 17, 2018
- First Published October 30, 2018.
Author Disclosures
- Julia Schubert, MD,
- Dirk Brämer, MD,
- Hagen B. Huttner, MD,
- Stefan T. Gerner, MD,
- Hannah Fuhrer, MD,
- Nico Melzer, MD,
- Andre Dik, MD,
- Harald Prüss, MD,
- Lam-Than Ly, MD,
- Kornelius Fuchs, MD,
- Frank Leypoldt, MD,
- Gunnar Nissen, MD,
- Ingo Schirotzek, MD,
- Christian Dohmen, MD,
- Julian Bösel, MD,
- Jan Lewerenz, MD,
- Franziska Thaler, MD,
- Andrea Kraft, MD,
- Aleksandra Juranek, MD,
- Marius Ringelstein, MD,
- Kurt-Wolfram Sühs, MD,
- Christian Urbanek, MD,
- André Scherag, PhD,
- Christian Geis, MD,
- Otto W. Witte, MD,
- Albrecht Günther, MD;
- for the GENERATE and IGNITE network
- Julia Schubert, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dirk Brämer, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hagen B. Huttner, MD,
(1) Advisory Board fees from Boehringer Ingelheim (2) Advisory Board fees from Medtronic
NONE
(1) Travel honoraria from Boehringer Ingelheim
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research Foundation (DFG), grant number Hu1961/2-1
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan T. Gerner, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hannah Fuhrer, MD,
NONE
NONE
(1) travel funding, commercial, hotel costs
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nico Melzer, MD,
1. Commercial Advisory Board, Alexion Pharmaceuticals, Germany
NONE
1. Biogen Idec, honoraria for lecturing and travel expenses for attending meetings 2. GlaxoSmith Kline, honoraria for lecturing and travel expenses for attending meetings 3. Teva, honoraria for lecturing and travel expenses for attending meetings 4. Fresenius Medical Care, honoraria for lecturing and travel expenses for attending Meetings 5. Alexion Pharmaceuticals Germany, honoraria for lecturing and travel expenses for attending Meetings
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Immunoadsorption, (5%), 3 years
1. Fresenius Medical Care 2. Diamed 3. Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andre Dik, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Harald Prüss, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lam-Than Ly, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kornelius Fuchs, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Leypoldt, MD,
(1) Roche, Biogen
NONE
(1) Grifols (2) Teva (3) Biogen (4) Fresenius (5) Bayer (6) Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Institute of Laboratory Medicine, University Hospital Schleswig- Holstein Campus Kiel, Germany, commercial antibody testing service, 20%
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gunnar Nissen, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ingo Schirotzek, MD,
(1) Merck Serono (2) Sanofi Aventis (3) BARD
NONE
(1) Merck Serono (2) Sanofi Aventis (3) TEVA (4) Biogen (5) Novartis (6) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Dohmen, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julian Bösel, MD,
NONE
NONE
Speaker honoraria and travel Support from Bard, Zoll, Sedana Medical, Medtronic, Boehringer Ingelheim
Neurocritical Care (editorial board, reviewer, 3y); Neurology Research and Practice (Editorial board, 1y)
NONE
Neuro-Intensivmedizin, Thieme, 2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
DGNI, start-up funding for SETPOINT2 study
NONE
NONE
NONE
NONE
NONE
NONE
- Jan Lewerenz, MD,
NONE
NONE
(1) Euroimmun, speaker's honoraria, 2014 (2) Teva, speaker's honoraria, 2016 (3) CHDI, travel,2018 (4) Movement Disorders Society, speaker's honoraria, 2018
NONE
NONE
NONE
NONE
NONE
NONE
(1) JL oversees a laboratory of a non-profit hospital that offers testing for antineuronal and onconeuronal antibodies.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Franziska Thaler, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrea Kraft, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aleksandra Juranek, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marius Ringelstein, MD,
NONE
NONE
1. Novartis, funding for speaking at a conference. 2. Ipsen, funding for speaking at a conference. 3. Bayer Healthcare, funding for travel to a conference. 4. Biogen Idec, funding for travel to a conference. 5. Genzyme, funding for travel to a conference. 6. TEVA, funding for travel to a conference. 7. Merz, funding for travel to a conference. 8. Merck, funding for travel to a conference.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kurt-Wolfram Sühs, MD,
(1)Merck
NONE
(1) Merck funding for travel for conference
NONE
NONE
NONE
Hannover Medical School; Carl-Neuberg-Stra?e 1; 30625 Germany; Dept. Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Urbanek, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- André Scherag, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Geis, MD,
NONE
NONE
(1) Merck-Serono, travel funding
(1) Frontiers Neurology, guest editor, 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) German research council, GE 2519/3-1, from 2014 (2) German research council, TRR-SFB 166, from 2015 (3) German ministry of education, CSCC, from 2013
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Otto W. Witte, MD,
NONE
NONE
NONE
(1) Das Neurophysiologie-Labor (2) Zeitschrift f?r klinische Neurophysiologie
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) German Research Foundation (DFG) 2012-2015, Wi 830/10- 1 (2) Thurigean Ministry for Education and Research, 2009 - 2012 PE 114-1 (3) Federal Ministry for Research and Technology, 2009 - 2015 JenAge PTJ 0315581B (4) Federal Ministry for Research and Technology, 2009 - 2015, Bernstein Fokus 01GQ0923 (5) European Union, ARGES, 2006 - 2010, LSHB-CT-2006- 018936 (6) German Research Foundation Research Unit 1738 2012-2018 (7) Else Kr?ner Foundation Jena School for Aging Medicine
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Albrecht Günther, MD;
NONE
NONE
funding for travel and speaker honoraria, expert panels: Merz, Ipsen, Boehringer-Ingelheim, Pfizer, Daiichi Sankyo, Bayer (2007-2018)
Section Editor for
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- for the GENERATE and IGNITE network
- From the Hans-Berger-Department of Neurology (J.S., D.B., C.G., O.W.W., A.G.), Jena University Hospital; Department of Neurology (H.B.H., S.T.G.), University Hospital Erlangen; Department of Neurology and Neurophysiology (H.F), University Hospital Freiburg; Department of Neurology (N.M., A.D.), University Hospital Münster; Department of Neurology (H.P., L.-T.L), Charité University Medicine Berlin; Department of Neurology (K.F.), Bezirksklinikum Regensburg; Neuroimmunology Section (F.L., G.N.), Institute of Clinical Chemistry and Department of Neurology, University Hospital Schleswig-Holstein, Kiel; Department of Neurology (I.S.), University Hospital Giessen; Center for Neurology and Psychiatrics (C.D.), University Hospital Köln; Department of Neurology (J.B.), University Hospital Heidelberg; Department of Neurology (J.B.), Klinikum Kassel; Department of Neurology (J.L.), University Hospital Ulm; Institute of Clinical Neuroimmunology (F.T.), Ludwig-Maximillians-University München; Department of Neurology (A.K.), Martha Maria Hospital Halle; Department of Neurology (A.J.), Dortmund Hospital; Department of Neurology (M.R.), Medical Faculty, Heinrich Heine University Düsseldorf; Department of Neurology (K.-W.S.), University Hospital Hannover; Department of Neurology (C.U.), Hospital Ludwigshafen; Institute of Medical Statistics, Computer and Data Sciences (A.S), Jena University Hospital; and Center for Sepsis Control and Care (A.S., C.G.), Jena University Hospital, Germany.
- Correspondence
Dr. Günther Albrecht.guenther{at}med.uni-jena.de
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
The spectrum of acute encephalitisCauses, management, and predictors of outcomeTarun D. Singh, Jennifer E. Fugate, Alejandro A. Rabinstein et al.Neurology, December 24, 2014 -
Article
Anti-NMDAR encephalitisA single-center, longitudinal study in ChinaXiaolu Xu, Qiang Lu, Yan Huang et al.Neurology: Neuroimmunology & Neuroinflammation, October 16, 2019 -
Article
Autoimmune encephalitisA costly conditionJesse Cohen, Javier Sotoca, Shikha Gandhi et al.Neurology, January 23, 2019 -
Article
Liver transplantation as a rescue therapy for severe neurologic forms of Wilson diseaseAurélia Poujois, Rodolphe Sobesky, Wassilios G. Meissner et al.Neurology, May 12, 2020